Skadden, Arps, Slate, Meagher & Flom and Gibson, Dunn & Crutcher have taken on lead roles in New Jersey-headquartered pharmaceutical group Merck & Co.’s $3 billion acquisition of EyeBio, an ophthalmology-focused drug development company in the U.K.

It is the latest example of a U.S. business acquiring a U.K. company, a growing trend in U.K. mergers and acquisitions that is furnishing U.S. law firms with plenty of work.